Healthcare: AZ widens agency net on global neuroscience PR

AstraZeneca (AZ) has held discussions with a quartet of agencies over how it promotes a brace of neuroscience products, with global PR contracts for Seroquel and Cerovive up for grabs.

The Anglo-Swedish firm wants to investigate 'fresh ways of communicating' its neuroscience brands, said AZ global director of product PR Margaret Morgan.

Cohn & Wolfe, Porter Novelli, Chandler Chicco Agency and Red Door Communications have already presented credentials.

Morgan told PRWeek: 'We may see some more agencies. Things are exploratory at this stage.'

Seroquel is a fast-growing treatment for schizophrenia, while Cerovive is a pre-launch treatment for strokes.

Seroquel is currently promoted on a global basis by Shire Health International; Fleishman-Hillard's healthcare division (formerly CPR Worldwide) handles Cerovive globally.

'These agencies shouldn't feel threatened. This doesn't necessarily mean one or both of these agencies will be replaced - we may add to our portfolio,' Morgan said.

AZ announced last week that it plans to press ahead with further clinical trials of Cerovive; it is to file regulatory submissions in the second half of next year.

Data from a trial involving more than 1,700 patients, unveiled last week, showed Cerovive achieved 'statistical significance' in reducing disability after a major stroke.

Agencies with country-specific remits, such as Edelman (Seroquel in the US) and Munro & Forster Communications (Seroquel in the UK), are not affected by the review.

Morgan, AZ global PR manager for neuroscience Louise Marland and brand marketing teams are co-ordinating the review from AZ's Cheshire offices.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.